Living kidney transplantation without perioperative anticoagulation therapy for a patient with heparin-induced thrombocytopenia.
end‐stage renal disease
heparin
heparin‐induced thrombocytopenia
kidney transplantation
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
27
11
2019
accepted:
28
01
2020
entrez:
4
8
2020
pubmed:
4
8
2020
medline:
4
8
2020
Statut:
epublish
Résumé
Heparin-induced thrombocytopenia is an antibody-mediated acquired prothrombotic state induced by heparin exposure. The risk of thromboembolic diseases in kidney transplantation with heparin-induced thrombocytopenia without perioperative anticoagulation has not been determined. A 64-year-old male hemodialysis patient with heparin-induced thrombocytopenia was referred to our hospital for living kidney transplantation. Anti-heparin-induced thrombocytopenia antibody was positive at the time of referral; however, it turned negative 4 months after heparin cessation during hemodialysis sessions. Living kidney transplantation by donation from his wife was performed using the standard technical procedure. Both heparinization and application of medical equipment containing heparin were avoided; however, no anticoagulant was administered intra- and postoperatively. The graft kidney functioned immediately, and no thromboembolic event related to heparin-induced thrombocytopenia occurred. Kidney transplantation without perioperative anticoagulation therapy after disappearance of anti-heparin-induced thrombocytopenia antibody is a well-tolerated treatment option for patients with end-stage kidney disease.
Identifiants
pubmed: 32743478
doi: 10.1002/iju5.12148
pii: IJU512148
pmc: PMC7292195
doi:
Types de publication
Case Reports
Langues
eng
Pagination
86-89Informations de copyright
© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Thromb Haemost. 2008 Sep;100(3):498-504
pubmed: 18766268
Circulation. 2004 Nov 2;110(18):e454-8
pubmed: 15520327
Transplant Proc. 2007 Dec;39(10):3481-4
pubmed: 18089414
N Engl J Med. 1995 May 18;332(20):1330-5
pubmed: 7715641
Ann Transplant. 2018 Apr 06;23:232-235
pubmed: 29622761
Pediatr Transplant. 2006 Feb;10(1):114-8
pubmed: 16499600
Chest. 2012 Feb;141(2 Suppl):e495S-e530S
pubmed: 22315270
Masui. 2014 Mar;63(3):346-9
pubmed: 24724449
J Thromb Haemost. 2006 Apr;4(4):759-65
pubmed: 16634744
Br J Haematol. 2012 Dec;159(5):528-40
pubmed: 23043677
Isr Med Assoc J. 2014 Jan;16(1):61-2
pubmed: 24575510
Am J Hematol. 2009 Apr;84(4):251-3
pubmed: 19260122
Int Urol Nephrol. 2012 Jun;44(3):991-4
pubmed: 21424572
World J Transplant. 2016 Mar 24;6(1):165-73
pubmed: 27011914
Rinsho Ketsueki. 2017;58(7):875-882
pubmed: 28781287
Am J Transplant. 2005 Jun;5(6):1537-40
pubmed: 15888065
Blood. 2017 May 25;129(21):2864-2872
pubmed: 28416511
Am J Case Rep. 2019 Jul 09;20:980-987
pubmed: 31285416
J Cardiothorac Vasc Anesth. 2017 Feb;31(1):354-364
pubmed: 27746016